December 15, 2020 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Oxford Nanopore and SourceBio announce commercial partnership for UK COVID-19 testing service

Tue 15th December 2020 Oxford Nanopore’s rapid LamPORE COVID-19 test to be made available via SourceBio accredited lab facilities. Oxford Nanopore Technologies Limited (“Oxford Nanopore”), a leading next generation DNA/RNA sequencing technology company and SourceBio International plc (“SourceBio”), an international provider of integrated state of the art laboratory services and products, announce a strategic commercial... Read more

December 15, 2020 Clinical Research/Diagn. Lab Top-10 Other Lab Products/Services

Thermo Fisher Scientific Expands Clinical Supply Chain Services in Europe

Clinical supply and specialized cold chain storage sites in Germany support growing demand for expanded services WALTHAM, Mass., Dec. 15, 2020 /PRNewswire/ — To meet accelerating demand for robust clinical supply chain services throughout Europe, Thermo Fisher Scientific has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany.... Read more

December 14, 2020 Clinical Research/Diagn. Lab Top-10 Life Science Tools PAI Top-10 PR/Corporate Product Launch

EUROIMMUN Receives CE Mark for New PCR Test to Differentiate Between COVID-19 and Flu

Company expands testing portfolio for acute diagnostics of COVID-19 WALTHAM, Mass. – December 14, 2020 – EUROIMMUN, a PerkinElmer, Inc. Company, today announced the launch of the CE marked EURORealTime SARS-CoV-2/Influenza A/B for direct detection of SARS-CoV-2, influenza virus type A and influenza virus type B. It expands the testing portfolio for acute COVID-19 diagnostics... Read more

December 10, 2020 Bio/Pharma/CRO Clinical Research/Diagn.

Roche presents exploratory data from the Phase III IMvigor010 study in early bladder cancer at the ESMO Immuno-Oncology Virtual Congress 2020

People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNA The goal of current treatment in people with MIUC is to provide early intervention to reduce the risk of the disease recurring or spreading... Read more

December 8, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay

December 8, 2020 at 10:17 AM EST CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company’s SARS-CoV-2 molecular diagnostic test on the Revogene® platform. The... Read more

December 8, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

LGC’s Anti-SARS-CoV-2 controls kit now CE Marked

LGC is pleased to announce that the ACCURUN® Anti-SARS-CoV-2 Reference Material Kit is now CE marked for in vitro diagnostic use (CE-IVD). With this change in regulatory status, the new product name is ACCURUN Anti-SARS-CoV-2 Controls Kit. Bearing the CE mark and IVD symbol signifies that the ACCURUN Anti-SARS-CoV-2 Controls Kit meets extensive design control requirements. ACCURUN... Read more

December 3, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

December 3, 2020 at 10:00 AM EST CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. This specialized master mix is designed... Read more

December 2, 2020 Clinical Research/Diagn. M&A, Partnerships

Regulus Therapeutics Collaborates with Bio-Techne for Biomarker Development

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial... Read more

December 1, 2020 Cell Analysis Tools Clinical Research/Diagn. Product Launch

Miltenyi Biotec launches all-in-one kits for stimulation and analysis of SARS-CoV-2–reactive T cells

T cell activation an important parameter in COVID-19; linked to execution and control of multiple mediators in controlling infections1, 2 BERGISCH GLADBACH, December 1st – Miltenyi Biotec today launches new all-in-one kits for the efficient stimulation and functional analysis of SARS-CoV-2‒reactive T cells. Specifically developed for fast and rapid detection in PBMC samples after stimulation with the SARS-CoV-2... Read more

November 30, 2020 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

LGC’s high-throughput PCR testing system for SARS-CoV-2 detection, submitted for Emergency Use Authorisation, capable of processing up to 35,000 tests per day

LGC’s high-throughput (HTP) RT-PCR testing system for SARS-CoV-2 has been submitted to the FDA for Emergency Use Authorisation (EUA). Testing labs can now leverage LGC’s unrivalled expertise in automated sample preparation and high-throughput RT-PCR workflows in a ready-to-deploy solution. As the need for SARS-CoV-2 testing for both diagnostic and screening applications continues to grow, many organisations are... Read more